Appearance
The PFA Race
Every PFA platform has safety problems. This page shows what FDA adverse event data reveals when you estimate per-procedure rates with the best available denominators.
The reporting rate gap has closed. VARIPULSE's MAUDE reporting rate dropped from 87 to 6.5 per 1,000 procedures as volume grew from ~3,000 to ~40,000. FARAPULSE reports at 4.8. The gap is now ~1.35x — within normal manufacturer variation, not the 7x inflation artifact it was at launch.
FARAPULSE (Boston Scientific)
Market leader. 500,000+ procedures globally. $1.9B EP revenue (FY2025). Approved for paroxysmal and persistent AFib. And 91 deaths in FDA filings — with growth stalling.
91 Deaths: What the Data Shows
| Root Cause (LLM extraction) | Count | % of deaths |
|---|---|---|
| Unknown (no root cause determined) | 51 | 56% |
| Design flaw (incl. software) | 16 | 18% |
| User error | 16 | 18% |
| Not yet extracted | 8 | 9% |
So what: 91 deaths across 500,000+ procedures is ~0.02%. The rate isn't the story. The story is that 56% of deaths have "unknown" root cause — and 16 deaths are attributed to design flaws, including 4 from a software bug (80% fatality from a product defect). Compare: 100% of VARIPULSE deaths have detailed follow-up investigations with root cause analysis.
MANIFEST-US Registry (41,968 patients)
Published JACC Jan 2026. Largest US real-world PFA safety study:
- Major complication rate: ~0.6%
- Stroke: ~0.1% (1 in 1,000)
- Death: ~0.05% (1 in 2,000)
- Zero esophageal fistula or pulmonary vein stenosis
So what: MANIFEST-US is BSC's strongest asset. J&J has no comparable registry. At 40,000 procedures, J&J has the volume to build one — and should.
ADVENT 4-Year Data (2026 AF Symposium)
First-ever 4-year comparative PFA vs thermal data:
- PFA effectiveness: 72.8% vs 64.1% thermal
- Freedom from re-intervention: 85.6% vs 78.6%
So what: Long-term PFA durability is proven. This benefits the entire PFA category, including VARIPULSE.
FARAPULSE vs VARIPULSE: Updated Rates
| Per 10,000 procedures | FARAPULSE | VARIPULSE | Gap |
|---|---|---|---|
| Deaths | 1.8 | 0.75 | VARIPULSE 2.4x better |
| Mfg defects | 5.7 | 3.0 | VARIPULSE 1.9x better |
| Design flaws | 2.1 | 7.8 | FARAPULSE better (note below) |
| MAUDE reports per 1K | 4.8 | 6.5 | Comparable (~1.35x) |
VARIPULSE design flaw rate reflects 31 LLM-extracted flaws in 40K procedures. At 40K procedures, 75% have LLM extraction (196/260 events), so this rate is reasonably representative.
What holds up at any sample size:
- 56% of FARAPULSE deaths have unknown root cause vs 0% of VARIPULSE's
- 16 FARAPULSE design flaw deaths including 4 software deaths
- J&J paused voluntarily (Class I). BSC didn't pause for the same stroke signal (Class II).
BSC Pipeline and Earnings
- Q4 2025 miss: EP segment missed consensus by $33M ($649M actual). BSC stock dropped 18% on Feb 4.
- Farapoint: Focal PFA catheter, FDA approved Jan 2026. Limited market release. First PFA catheter designed for point-by-point ablation.
- Faraflex: Next-gen integrated map+ablate catheter. First cases Feb 2025 (Croatia, ELEVATE-PF study). 8 Fr vs 12 Fr Farawave. No FDA timeline.
- Persistent AF label: FDA approved July 2025. VARIPULSE does not yet have persistent AF indication.
- FARAWAVE recall (June 2025): Class 2 recall of ~500 first-gen catheters for electrode band cracking. Limited scope, single production run.
Affera / Sphere-9 (Medtronic)
The strategic threat. Not because of safety — because it changes the buying decision. When Affera enters a lab, there's no separate CARTO sale. Medtronic PFA revenue grew 300%+ YoY, and PFA now accounts for 75% of Medtronic's cardiac ablation revenue.
Growth Trajectory
- Q2 FY2026: Cardiac Ablation Solutions grew 71% YoY (128% in US)
- PFA revenue: 300%+ YoY growth, both US and international
- PFA share of ablation revenue: 75% (Affera cannibalizing PulseSelect as planned)
- Q3 FY2026 earnings: Due ~Feb 17, 2026. Critical data point.
Safety Profile (Volume Unknown)
| Affera | VARIPULSE | |
|---|---|---|
| FDA adverse events | 401 | 260 |
| Deaths | 5 | 3 |
| Design flaws | 32 | 31 |
| Electrical failures | 63 | — |
| Software bugs | 7 | — |
Per-procedure rates cannot be estimated — Medtronic hasn't disclosed Affera volumes separately. The 63 electrical failures (most common failure mode) reflect the risk of integrated mapping/ablation: when one function fails, both are lost.
Affera Monthly Trend
Affera events accelerated through 2025: from 3/month (Q1 2025) to 28-56/month (Q4 2025). Five deaths appeared March-July 2025. No deaths since July 2025 (6 months clean). 32 design flaws and 25 manufacturing defects suggest ongoing product maturation.
Where Each Wins
- Affera: Simple AF PVI. No capital equipment. Faster setup. Lower per-case cost. Dual energy (PFA + RF) in one catheter.
- CARTO + VARIPULSE: Complex anatomy, redo procedures, VT (QDOT MICRO), training, multi-catheter workflows.
PulseSelect (Medtronic)
First PFA system approved (Dec 2023). ~30,000 procedures globally (est). Worst manufacturing quality in PFA and declining volume.
| Per 10,000 procedures | PulseSelect | FARAPULSE | VARIPULSE |
|---|---|---|---|
| Deaths | 3.7 | 1.8 | 0.75 |
| Mfg defects | 44.3 | 5.7 | 3.0 |
So what: 44.3 mfg defects per 10K is 8x FARAPULSE and 15x VARIPULSE. PulseSelect peaked at 117 events/month (June 2025), then declined to 31 in January 2026 — a 74% drop as Medtronic's own customers switch to Affera.
Abbott (Volt PFA)
FDA approved December 22, 2025. VOLT-AF IDE data (392 patients) presented at 2026 AF Symposium:
| Metric | Volt PFA |
|---|---|
| PAF effectiveness (12 mo) | 84.2% |
| Re-ablation rate | <6% |
| Hemolysis (clinically relevant) | 0% |
| Esophageal injury | 0% |
| Applications per vein | 4.6 |
| Same-day potential | High (conscious sedation) |
So what: 84.2% PAF effectiveness is competitive. Zero hemolysis is notable — this is a class-wide PFA concern and Abbott claims to have solved it. Conscious sedation instead of general anesthesia is a genuine ASC advantage.
Abbott projects ~3% PFA share in 2026. Not an immediate volume threat. But if hemolysis and sedation claims hold in broader use, Volt could own the ASC segment.
Adoption Trends
FARAPULSE (blue) | PulseSelect (orange) | Affera (green) | VARIPULSE (red)
So what:
- FARAPULSE peaked Q3, dropped Q4. BSC missed EP consensus by $33M. Growth era ending.
- PulseSelect collapsed 46% Q2-Q4. Medtronic customers switching to Affera.
- Affera grew 77% across the year. Fastest-growing PFA platform.
- VARIPULSE grew 90% (39-74) and is accelerating from 3K to 40K procedures globally.
- New entrants (2026 AF Symposium): FieldForce PFA (first-in-human), Arga Medtech CSE PFA (94% lesion durability), CardioFocus OptiShot. The category is getting more competitive.
FDA adverse event data, company-reported procedure volumes, MANIFEST-US registry (41,968 patients), VOLT-AF IDE (392 patients), company earnings. See Method.